RT Journal Article
SR Electronic
T1 An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.27.20189548
DO 10.1101/2020.09.27.20189548
A1 Pu, Jing
A1 Yu, Qin
A1 Yin, Zhifang
A1 Zhang, Ying
A1 Li, Xueqi
A1 Li, Dandan
A1 Chen, Hongbo
A1 Long, Runxiang
A1 Zhao, Zhimei
A1 Mou, Tangwei
A1 Zhao, Heng
A1 Feng, Shiyin
A1 Xie, Zhongping
A1 Wang, Lichun
A1 He, Zhanlong
A1 Liao, Yun
A1 Fan, Shengtao
A1 Yin, Qiongzhou
A1 Jiang, Ruiju
A1 Wang, Jianfeng
A1 Zhang, Lingli
A1 Li, Jing
A1 Zheng, Huiwen
A1 Cui, Pingfang
A1 Jiang, Guorun
A1 Guo, Lei
A1 Xu, Mingjue
A1 Yang, Huijuan
A1 Lu, Shan
A1 Wang, Xuanyi
A1 Gao, Yang
A1 Xu, Xingli
A1 Cai, Linrui
A1 Zhou, Jian
A1 Yu, Li
A1 Chen, Zhuo
A1 Hong, Chao
A1 Du, Dan
A1 Zhao, Hongling
A1 Li, Yan
A1 Ma, Kaili
A1 Ma, Yunfei
A1 Liu, Donglan
A1 Yao, Shibao
A1 Li, Changgui
A1 Che, Yanchun
A1 Liu, Longding
A1 Li, Qihan
YR 2020
UL http://medrxiv.org/content/early/2020/10/06/2020.09.27.20189548.abstract
AB BACKGROUND In-depth investigations of the safety and immunogenicity of inactivated SARS-CoV-2 vaccines are needed.METHOD In a phase I randomized, double-blinded, and placebo-controlled trial involving 192 healthy adults 18-59 years of age, two injections of three different doses (50 EU, 100 EU and 150 EU) of an inactivated SARS-CoV-2 vaccine or the placebo were administered intramuscularly with a 2- or 4-week interval between the injections. The safety and immunogenicity of the vaccine were evaluated within 28 days.FINDING In this study, 191 subjects assigned to three doses groups or the placebo group completed the 28-day trial. There were 44 adverse reactions within the 28 days, most commonly mild pain and redness at the injection site or slight fatigue, and no abnormal variations were observed in 48 cytokines in the serum samples of immunized subjects. The serum samples diluted from 1:32 to 1:4096 and incubated with the virus did not show antibody-dependent enhancement effects (ADEs) with regard to human natural killer cells, macrophages or dendritic cells. At day 14, the seroconversion rates had reached 92%, 100% and 96% with geometric mean titers (GMTs) of 18.0, 54.5 and 37.1, and at day 28, the seroconversion rates had reached 80%, 96% and 92% with GMTs of 10.6, 15.4 and 19.6in 0, 14 and 0, 28 procedures, respectively. Seroconversion was associated with the synchronous upregulation of ELISA antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte (CTL) response. Transcriptome analysis shaped the genetic diversity of immune response induced by the vaccine.INTERPRETATION In a population aged 18-59 years, this inactivated SARS-CoV-2 vaccine was safe and immunogenic.Trial registration NCT04412538FUNDING The National Key R&D Program of China (2020YFC0849700), the Program of Chinese Academy of Medicine Science and the Major Science and Technology Special Projects of Yunnan Province.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04412538Funding StatementThis work was supported by National Key R&D Program of China (2020YFC0849700), the Program of Chinese Academy of Medicine Science and the Major science and technology special projects of Yunnan Province.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Ethics Committee of the West China Second University Hospital, Sichuan University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were available.The raw microarray data were submitted to the National Genomics Data Center (NGDC) and are available (PRJCA003531).